The End of the Bigger Model: How Autonomous AI Reshapes Pharma and Power

The tech frontier has pivoted from raw parameter count to self-verifying autonomous systems capable of running businesses and compressing drug discovery timelines by 40%. This systemic shift threatens legacy pharmaceutical economics while democratizing AI through post-training specialization, forcing a global reckoning on digital sovereignty and labor structures.